Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation

Brain Injury

Volumn 13, Issue 1, 1999, Pages 63-68

  Karli, David C ^b   Burke, David T ^a   Kim, Hyun Jung ^b   Calvanio, Ronald ^b   Fitzpatrick, Maureen ^b   Temple, Deb ^b   Macneil, Maryann ^b   Pesez, Kristine ^b   Lepak, Paige ^a  

^a and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGITATION; ANTICHOLINERGIC EFFECT; ARTERIOVENOUS MALFORMATION; ARTICLE; ATAXIA; BEHAVIOR; BRAIN DYSFUNCTION; BRAIN HEMORRHAGE; BRAIN INJURY; CASE REPORT; CONFUSION; DYSARTHRIA; EDEMA; FEMALE; FRONTAL LOBE; HALLUCINATION; HUMAN; HYPERACTIVITY; NERVOUSNESS; REHABILITATION; SOCIOLOGY;

EID: 0032896038     PISSN: 02699052     EISSN: None     Source Type: Journal    
DOI: 10.1080/026990599121908     Document Type: Article

References (14)

1. KRAUS, M. and MAKI, P.: Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: Case studies and review. Journal of Neuropsychiatry and Clinical Neurosciences, 9: 222-230, 1997.
2. MARIN, R. S. and FOGEL, B. S.: Apathy: a treatable syndrome. Journal of Neuropsychiatry and Clinical Neurosciences, 7: 23-30, 1995.
3. NICKELS, J. L., SCHNEIDER, W. N., DOMBOVOY, M. L. et al.: Clinical use of amantadine in brain injury rehabilitation. Brain Injury, 8: 709-718, 1994.
4. CHANDLER, M. C., BARNHILL, J. L. and GUALTIERI, C.T.: Amantadine for the agitated head injury patient. Brain Injury, 4: 309-311, 1988.
5. FUGATE, L. P. and SPACEK, L. A.: Measurement and treatment of agitation following traumatic brain injury: II. A survey of the brain injury special interest group of the American Academy of PM&R. Archives of Physical Medicine and Rehabilitation, 78: 924-928, 1997.
6. GAULTIERI, T., CHANDLER, M. and COONS-BROWN, L.: Amantadine: a new clinical profile for traumatic brain injury. Clinical Neuropharmacology, 12: 258-270, 1989.
7. LAL, S., MERBTIZ, C. P. and GRIP, J. C.: Modification of function in head injured patients with sinemet. Brain Injury, 2: 225-233, 1988.
8. POWELL, J. H., AL-ADAWI, S., MORGAN, J. et al: Motivational deficits after brain injury: effects of bromocriptine on 11 patients. Journal of Neurology, Neurosurgery and Psychiatry, 60: 416-421, 1996.
9. WOLF, A. P. and GLECKMAN, A. D.: Sinemet and brain injury: functional versus statistical change and suggestions for future research designs. Brain Injury, 9: 487-493, 1995.
10. HORVATH, T. and MEARS, R.: L-Dopa and Arousal. Journal of Neurology, Neurosurgery and Psychiatry, 37: 416-421, 1974.
11. ROCA, R. P., SANTMEYER, K., GLOTH, M. et al.: Improvements in activity and appetite among long term care patients treated with amantadine: A clinical report. Journal of the American Geriatric Society, 38: 675-677, 1990.
12. VAN REEKUM, R., BAYLEY, M., GARNER, S. et al: N of 1 study: amantadine for the motivational syndrome in a patient with traumatic brain injury. Brain Injury, 9: 49-53, 1995.
13. COHEN, R. A. and FISHER, M.: Amantadine treatment of fatigue associated with multiple sclerosis. Archives of Neurology, 46: 676-680, 1989.
14. HORIGUCHI, J., INAMI, Y. and SHODA, T.: Effects of long term amantadine treatment on clinical symptoms and EEG of a patient in a vegetative state. Clinical Neuropharmacology, 13: 84-88, 1990.